Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cholesterol reduction therapy: a double-edged knife

H T Ong1

  • 1Gleneagles Medical Centre, Penang.

The Medical Journal of Malaysia
|June 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oncolytic measles virus-induced cell killing in radio-resistant and drug-resistant nasopharyngeal carcinoma.

The Malaysian journal of pathology·2024
Same author

Genetically engineered human umbilical cord-derived mesenchymal stem cells expressing human interleukin-12 and in vitro growth inhibition against lung adenocarcinoma cells.

The Malaysian journal of pathology·2023
Same author

Myosin IIA and formin dependent mechanosensitivity of filopodia adhesion.

Nature communications·2019
Same author

Assessing and Treating Cardiovascular Risk: Traditional Moderation is the Way to Go.

The Medical journal of Malaysia·2014
Same author

Cardiovascular effects of common analgesics.

The Medical journal of Malaysia·2013
Same author

Beta-blockers in Cardiovascular Disease: Do not throw out the baby with the bathwater.

The Medical journal of Malaysia·2013

Cholesterol reduction benefits cardiovascular health but doesn't lower overall mortality. Potential behavioral side effects necessitate individualized risk-benefit assessment for patients.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Behavioral Science

Background:

  • Cholesterol reduction effectively lowers cardiovascular morbidity and mortality in both healthy and diseased populations.
  • Angiographic studies confirm that cholesterol-lowering therapy can regress atherosclerotic plaques and prevent new atheroma formation.
  • Despite cardiovascular benefits, cholesterol-lowering drug trials consistently fail to demonstrate a reduction in overall mortality.

Purpose of the Study:

  • To evaluate the overall efficacy and safety of cholesterol reduction therapies.
  • To investigate the potential link between cholesterol reduction and adverse behavioral outcomes.
  • To determine the appropriate patient populations for cholesterol-lowering interventions.

Main Methods:

  • Review of clinical trial data on cholesterol-lowering drugs.

Related Experiment Videos

  • Analysis of angiographic studies assessing plaque regression.
  • Examination of epidemiological data linking cholesterol levels to behavioral outcomes.

    • Main Results:

    • Cholesterol reduction significantly reduces ischemic cardiovascular events and mortality in specific patient groups.
    • No consistent reduction in overall mortality has been observed across cholesterol-lowering drug trials.
    • An excess of suicides, homicides, and violent behaviors has been anecdotally attributed to cholesterol reduction.

    Conclusions:

    • Cholesterol reduction offers significant cardiovascular benefits, particularly for patients with existing coronary artery disease.
    • The inability to reduce overall mortality and potential behavioral side effects warrant careful consideration.
    • Individualized risk-benefit assessments are crucial for determining the appropriateness of cholesterol-lowering therapy.